Vertigo

Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results

Retrieved on: 
Wednesday, April 10, 2024

HAMILTON, BERMUDA -- April 10, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business update and reported its full year 2023 financial results.

Key Points: 
  • "Altamira emerged from the 2023 business year as a stronger and more focused company," commented Thomas Meyer, Altamira Therapeutics' founder, Chairman, and CEO.
  • "We keep progressing with our RNA delivery business, concluding recently our second collaboration agreement with another exciting biotech company.
  • Altamira expects to make further progress in 2024 with the strategic repositioning by partnering its inner ear therapeutics assets.
  • Altamira’s Senior Management will hold an investor call today, Wednesday, April 10, 2024, at 8:30 a.m. EDT to discuss its business update and full-year 2023 results.

AUO Leads Micro LED Ecosystem Dream Team toward Unlocking New Advances in Diverse Field Applications

Retrieved on: 
Tuesday, April 16, 2024

HSINCHU, April 16, 2024 /PRNewswire/ -- Taiwan's display industry leads the world, continually integrating new and diverse applications into people's lives with advanced smart display technologies. AUO has dedicated years to developing the ultimate Micro LED display technology, forging alliances with ecosystem partners to enable mass production through cross-domain integration and expediting the process from research and development to commercialization. The company now partners with a Taiwan-based dream team as it develops further solutions for the diverse applications of Micro LED display technology in various fields. At Touch Taiwan 2024, with a focus on "Beyond Display.See the Possibilities", AUO will showcase the various possibilities of Micro LED display technology applied to everyday life. From large-size to high-transparency Micro LED displays, these innovations extend to applications in smart mobility and retail to healthcare. By incorporating green technologies, AUO continues to create new value in the display industry.

Key Points: 
  • The company now partners with a Taiwan-based dream team as it develops further solutions for the diverse applications of Micro LED display technology in various fields.
  • Meanwhile, the company has integrated its supply chain to establish a comprehensive Micro LED ecosystem, partnering with Ennostar and PlayNitride to form a Micro LED dream team, securing key raw materials and manufacturing processes.
  • It will strive to enhance AUO's cost competitiveness in Micro LED products and accelerate the commercialization of Micro LED.
  • These features offer a glimpse of the ultimate applications of AUO's Micro LED display technology across a variety of fields.

The Vatican says gender theory threatens human dignity – but Judith Butler believes the ‘threat’ is social change

Retrieved on: 
Tuesday, April 9, 2024

It has become an “overdetermined” concept, “absorbing wildly different ideas of what threatens the world”, writes American feminist philospher Judith Butler.

Key Points: 
  • It has become an “overdetermined” concept, “absorbing wildly different ideas of what threatens the world”, writes American feminist philospher Judith Butler.
  • For the Vatican, the traditional family will be ruined and children are now vulnerable to “ideological colonization”.
  • And for right-wing politicians and heads of state, (from Liberal senator Alex Antic, who believes gender dysphoria is a “trend”, to Marjorie Taylor Greene and Vladimir Putin), gender is a weapon of social destruction.
  • Butler’s overarching argument is that “gender” – the overdetermined concept to which “anti-gender ideologists” object –  is really a nightmarish bogeyman, a “phantasm with destructive powers, one way of collecting and escalating multitudes of modern panics”.
  • Read more:
    Judith Butler: their philosophy of gender explained

Misplaced fears and misunderstandings

  • The first, to which much of the book is dedicated, is to expose the absurdity of arguments against gender ideology.
  • Butler demonstrates the ways “gender ideology” critics invert, externalise and project the very harms they claim “gender ideologists” pose.
  • Then there’s the supposed threat of sexual violence to cisgender women if transgender women are allowed into single-sex spaces like prisons.
  • Read more:
    'Toxic masculinity': what does it mean, where did it come from – and is the term useful or harmful?

More than two sexes

  • Feminists like Butler reject “sexual dimorphism”: the belief there are two, and only two, sexes.
  • But we expect to find two sexes because that is how many sexes we have learned to see.
  • And we look for two sexes because we only recognise two genders.
  • And because we expect to find two sexes in humanity, we automatically start to explain away any evidence (like intersex diversity) that would contradict this received truth.

Fighting back

  • These rules, we think, apply both to ourselves and others.
  • To critics, “gender ideologues” are breaking all the organisational rules of gender, inverting all sense and order.
  • When we question gender as an organising principle, it introduces further questions about the right way to live.
  • Ultimately, Butler’s point is that while gender seems scary to many, the reality is: it’s not.
  • Take a pause and ask, they suggest: what are the agendas of those who may try to convince you otherwise?
  • But in imagining a shared future together, we can “emerge into a world committed to cohabitation and equality across difference”.


Louise Richardson-Self receives funding from the Australian Research Council for two projects: DE190100719: Hate Speech Against Women Online: Concepts and Countermeasures; and DP200100395: Religious Freedom, LGBT+ Employees, and the Right to Discriminate.

Billy Idol to Celebrate 40th Anniversary of Landmark Album Rebel Yell With Deluxe Expanded Edition Due April 26 via UMe

Retrieved on: 
Wednesday, March 6, 2024

Rock legend Billy Idol is set to celebrate the 40th anniversary of his landmark album Rebel Yell with a deluxe expanded edition due April 26 via Capitol/UMe.

Key Points: 
  • Rock legend Billy Idol is set to celebrate the 40th anniversary of his landmark album Rebel Yell with a deluxe expanded edition due April 26 via Capitol/UMe.
  • View the full release here: https://www.businesswire.com/news/home/20240306135533/en/
    Billy Idol to Celebrate 40th Anniversary of Landmark Album Rebel Yell With Deluxe Expanded Edition Due April 26 via UMe (Graphic: Business Wire)
    Originally released in November 1983, Rebel Yell is the twice-platinum follow-up to Idol’s self-titled debut.
  • American Songwriter raves that Billy Idol: State Line is “outstanding…a must-see for even casual fans.” Order the DVD HERE and the Blu-ray HERE .
  • In January, Idol cemented his name among Hollywood legends with the first Walk of Fame Star of 2023.

Otolith Labs Expands Leadership Team with the Appointment of Dan Wagner as its Chief Commercial Officer and Raphael Michel to its Board of Directors

Retrieved on: 
Wednesday, February 21, 2024

Otolith Labs, a medical technology company developing non-invasive wearable medical devices for the treatment of vestibular disorders, appointed Dan Wagner as Chief Commercial Officer (CCO) and Raphael Michel as an independent Board member.

Key Points: 
  • Otolith Labs, a medical technology company developing non-invasive wearable medical devices for the treatment of vestibular disorders, appointed Dan Wagner as Chief Commercial Officer (CCO) and Raphael Michel as an independent Board member.
  • Otolith Labs’ technology is a head-worn wearable device being investigated for the treatment of vertigo episode symptoms associated with vestibular migraines.
  • “Dan has been working with Otolith in an advisory role for over 5 years, so we are thrilled to have him full-time.
  • “Raphael is one of our earliest industry advisors and has been providing critical counsel to Otolith Labs since 2016.

The Inner Circle Acknowledges, London L. Jones, DC, as a Top Pinnacle Professional

Retrieved on: 
Monday, February 19, 2024

FRESNO, Calif., Feb. 19, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, London L. Jones, DC, is acknowledged as a Top Pinnacle Professional for his contributions to the field of Chiropractic Medicine.

Key Points: 
  • FRESNO, Calif., Feb. 19, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, London L. Jones, DC, is acknowledged as a Top Pinnacle Professional for his contributions to the field of Chiropractic Medicine.
  • In the field since 1996, Dr. Jones practices chiropractic medicine and has completed extensive post-doctoral training in various areas of chiropractic medicine.
  • The doctor explained that chiropractic medicine is an alternative medicine that focuses on diagnosing and treating biomechanical disorders of the musculoskeletal system, primarily in the spine.
  • Considered an expert in advanced-quality chiropractic, Dr. Jones specializes in treating trauma and injuries related to auto accidents.

Why are so many Australians taking antidepressants?

Retrieved on: 
Thursday, February 8, 2024

Around one in seven Australians take antidepressants; more than 3.5 million of us had them dispensed in 2021–22.

Key Points: 
  • Around one in seven Australians take antidepressants; more than 3.5 million of us had them dispensed in 2021–22.
  • Guidelines mostly recommend antidepressants for more severe depression and anxiety but not as first-line treatment for less severe depression.
  • So why are so many Australians taking antidepressants and why are prescriptions rising?

Enter the antidepressant ‘blockbusters’

  • In the 1990s, pharmaceutical companies heavily promoted new selective serotonin reuptake inhibitors (SSRI) antidepressants, including Prozac (fluoxetine), Zoloft (sertraline) and Lexapro (escitalopram).
  • These drugs were thought to be less dangerous in overdoses and seemed to have fewer side effects than the tricyclic antidepressants they replaced.
  • Pharmaceutical companies marketed SSRIs energetically and often exaggerated their benefits, including by paying “key opinion leaders” – high-status clinicians to promote them.

Why are antidepressants prescribed?

  • GPs also prescribe antidepressants to patients experiencing distress but who don’t have a psychiatric diagnosis.
  • Another, who cried when informed she had breast cancer, was immediately offered a prescription for antidepressants.
  • Most patients believe antidepressants restore a chemical imbalance that underpins depression.
  • Antidepressants are emotional (and sexual) numbing agents – sometimes sedating, sometimes energising.
  • Around half of users have impaired sexual function and for some, this sexual dysfunction persists after stopping antidepressants.

How long do people take antidepressants?

  • Around half of patients who start antidepressants don’t like them and stop within weeks.
  • Of those who do take them for months, many continue to use them indefinitely, often for many years.
  • Read more:
    Antidepressants can cause withdrawal symptoms – here’s what you need to know

We need to adjust how we view mental distress

  • Overprescribing antidepressants is a symptom of our lack of attention to the social determinants of mental health.
  • GPs also need to ensure they discuss with their patients the potential adverse effects of antidepressants, and when and how to safely stop them.
  • But the fundamental problem is social and can only be properly addressed by meaningfully addressing inequality and changing community attitudes to distress.


Jon Jureidini receives research funding from MMRF. He is affiliated with Critical Psychiatry Network Australasia.

Professional Physical Therapy Announces New Clinic Opening in Dyker Heights, NY

Retrieved on: 
Wednesday, January 3, 2024

MELVILLE, N.Y., Jan. 3, 2024 /PRNewswire-PRWeb/ -- Professional Physical Therapy, a leading provider of outpatient physical therapy and rehabilitation services throughout New York, New Jersey, Connecticut, Massachusetts, and New Hampshire, announces the opening of a new state-of-the-art clinic in the heart of Dyker Heights, NY. This marks their third clinic opening in Brooklyn and their 34th clinic in New York City's 5 boroughs.

Key Points: 
  • MELVILLE, N.Y., Jan. 3, 2024 /PRNewswire-PRWeb/ -- Professional Physical Therapy, a leading provider of outpatient physical therapy and rehabilitation services throughout New York, New Jersey, Connecticut, Massachusetts, and New Hampshire, announces the opening of a new state-of-the-art clinic in the heart of Dyker Heights, NY.
  • This marks their third clinic opening in Brooklyn and their 34th clinic in New York City's 5 boroughs.
  • Services at Professional Physical Therapy in the Dyker Heights clinic include:
    Physical Therapy - Our physical therapists treat medical conditions that limit functional mobility and help develop a customized treatment plan to improve the ability to move, reduce pain, restore function, and prevent disability.
  • For more information and a list of all Professional Physical Therapy locations and services, please visit http://www.professionalpt.com

Human medicines European public assessment report (EPAR): Spravato, esketamine, Date of authorisation: 18/12/2019, Revision: 9, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Spravato, esketamine, Date of authorisation: 18/12/2019, Revision: 9, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Spravato, esketamine, Date of authorisation: 18/12/2019, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Wakix, pitolisant, Date of authorisation: 31/03/2016, Revision: 16, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Wakix, pitolisant, Date of authorisation: 31/03/2016, Revision: 16, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Wakix, pitolisant, Date of authorisation: 31/03/2016, Revision: 16, Status: Authorised